ערך בספרים למניה: Cadrenal Therapeutics Inc. (CVKD)

Book value per share data confirms the anticipation of final drug tests, although the orphan drug status is already priced in. Nephrologists' confidence in the anticoagulant's safety reduces stroke risks, while revenue is based on insurance fund payments for Tecarfarin in cardiology departments. The value of 1.32 expresses today's metric value, capturing the real capital of Cadrenal Therapeutics (CVKD) net of all liabilities.

Analyzing equity minus liabilities is key to assessing the financial stability of Cadrenal Therapeutics (CVKD). The trend in book value per share reflects the actual volume of net assets available to shareholders, which is critical for an R&D company developing Tecarfarin, a specialized anticoagulant for patients with renal failure.